2012
DOI: 10.1016/j.jchromb.2012.08.028
|View full text |Cite
|
Sign up to set email alerts
|

Insulin related compounds and identification

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2014
2014
2019
2019

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 25 publications
(26 reference statements)
0
1
0
Order By: Relevance
“…The best known impurities of insulin and insulin analogs are desamido A21 and desamido B3 derivatives ( 6 ). Other related proteins of insulins identified during drug production or storage are: des-Thr-insulin which is an undesirable side-product, di-Arg B31-B32 -insulin, and Arg-insulin, which are intermediates during insulin production, N αB1 carbamoyl insulin, N αA1 carbamoyl insulin ( 7 – 9 ) acetylated lispro insulin ( 10 ), desPhe B1 -N-oxalyl-Val B2 insulin ( 11 ), desPhe B1 -, desPhe B1 -N-formyl-Val B2 - and pyroGlu B4 insulin ( 12 ), covalent insulin dimers ( 13 ), insulin fragments ( 14 ), misincorporated A9 (Ser → Asn) human insulin ( 14 ) and insulin with amino acid residues oxidized to 3,4-dihydroxyphenylalanine (DOPA) and 2-amino-3-(3,4-dioxocyclohexa-1,5-dien-1-yl) propanoic acid (DOCH) ( 15 ). Such impurities present in a protein substance and dosage forms cannot exceed acceptable amounts in order to meet the Pharmacopoeia requirements ( 16 ).…”
Section: Introductionmentioning
confidence: 99%
“…The best known impurities of insulin and insulin analogs are desamido A21 and desamido B3 derivatives ( 6 ). Other related proteins of insulins identified during drug production or storage are: des-Thr-insulin which is an undesirable side-product, di-Arg B31-B32 -insulin, and Arg-insulin, which are intermediates during insulin production, N αB1 carbamoyl insulin, N αA1 carbamoyl insulin ( 7 – 9 ) acetylated lispro insulin ( 10 ), desPhe B1 -N-oxalyl-Val B2 insulin ( 11 ), desPhe B1 -, desPhe B1 -N-formyl-Val B2 - and pyroGlu B4 insulin ( 12 ), covalent insulin dimers ( 13 ), insulin fragments ( 14 ), misincorporated A9 (Ser → Asn) human insulin ( 14 ) and insulin with amino acid residues oxidized to 3,4-dihydroxyphenylalanine (DOPA) and 2-amino-3-(3,4-dioxocyclohexa-1,5-dien-1-yl) propanoic acid (DOCH) ( 15 ). Such impurities present in a protein substance and dosage forms cannot exceed acceptable amounts in order to meet the Pharmacopoeia requirements ( 16 ).…”
Section: Introductionmentioning
confidence: 99%